Quistogastrostomía y necrosectomía laparoscópica tras pseudoquiste pancreático

Introducción: El tratamiento de la Pancreatitis Aguda Necrotizante (PAN) y sus secuelas, ha experimentado un cambio sustancial desde  la incorporación del abordaje mínimamente invasivo secuencial ("Step-Up Approach").Caso Clínico.  Presentamos el caso de un paciente de 76 años con antecedentes de hipertensión arterial y dislipemia, que ingresó con una pancreatitis necrotizante litiásica y fallo de tres órganos (Respiratorio, Hemodinámico y Coagulación).  La evolución en UCI fue favorable con resolución del fallo multiorgánico, pero presentando una colección retropancreática de 20 cm de diámetro.   La estancia en planta fue favorable. La punción ecoguiada de la lesión no mostró células malignas, ni crecimiento de microorganismos.  El TAC a las 4 semanas demostró la presencia de una colección retrogástrico de 15x12 cm, con paredes definidas y presencia de abundantes restos sólidos en su interior, sugestivos de tejido necrótico.  Tras 45 días de ingreso, la paciente fue dada de alta a domicilio, con seguimiento en consulta externa, observando persistencia del pseudoquiste con restos necróticos.  Dada la persistencia del pseudoquiste después de 12 semanas, se decidió realizar quistogastrostomia laparoscópica con colecistectomía en el mismo acto quirúrgico.Intervención.  Se realizó un abordaje laparoscópico con 4 trócares, apreciándose una tumoración que abombaba el cuerpo y antro gátricos.  Se realizó una gastrostomía anterior con aspiración de abundante líquido y restos necróticos, así como una quistogastrostomía con endograpadora, necrosectomía  y colecistectomía.  El postoperatorio discurrió sin incidencias, con alta a los 10 días. La anatomía patológica informó de tejido pancreático necrosado sin atipias celulares.  La paciente permanece asintomática un año después de la intervención.Conclusiones. La cirugía mínimamente invasivo ha cambiado el abordaje de la PAN y sus complicaciones. El abordaje laparoscópico permite realizar quistogastrostomías y necrosectomías de una manera segura y en un sólo procedimiento, con el consiguiente beneficio para el paciente

Influence of portal vein/superior mesenteric vein resection on morbility, mortality and survival of patients with pancreatic ductal adenocarcinoma in the Balearic Islands

Introduction: Recent developments have enabled associate to standard pancreaticoduodenectomy (DPC), vascular resections to increase resectability in pancreatic cancer. Objectives: Analyze morbidity, mortality and survival of a consecutive series of patients with pancreatic cancer, in which a DPC with portal vein resection was performed, and compared it with a group of patients with standard DPC without venous resection. Methodology: Consecutive series of 67 patients who underwent a DPC ought to pancreatic ductal adenocarcinoma, between January 2005 and January 2015. Results: Standard resection (RV-) was performed in 49 cases, and a venous resection in another 18 patients (RV+). There were no significant differences in age (65 vs 68.9 years), ASA, or intraoperative transfusion. Duration of intervention was significantly lower in the RV- group (6.1 vs 6.7; p = 0.05). Morbidity grade III -IV was 14.2 % Clavien in the RV- group and 16.6 % in the RV + group (p = 0.87). There were no differences in hospital mortality (0 % vs 5.5%), or hospital stay (14.4 vs 15.2 days). The surgical margin involvement was more frequent in the RV+ group (18 % vs 50 % ; p = 0.003). One, 3 and 5 years survival was 77, 34 and 11% in the RV- group and 92, 23 and 8% in the group with venous resection. Conclusions: DPC with venous resection can be performed with morbidity and mortality rates similar to standard DPC1. Survival shows no significant difference between the two groups.Venous resection may increase resectability in a selected group of patients with pancreatic adenocarcinoma.Introducción: Los progresos recientes han permitido asociar a la duodenopancreatectomía cefálica estándar (DPC), resecciones vasculares para incrementar la resecabilidad en el cáncer de páncreas. Objetivos: Analizar la morbi-mortalidad y supervivencia de una serie consecutiva de pacientes con cáncer de páncreas, en los que se realizó una DPC con resección de vena porta y compararla con un grupo de pacientes con DPC estándar sin resección venosa. Material y métodos: Serie consecutiva de 67 pacientes intervenidos con adenocarcinoma ductal de páncreas, entre enero 2005 y enero 2015. Resultados: En 49 casos se realizó una resección estándar (RV-) y en 18 pacientes, una resección venosa (RV+). No hubo diferencias significativas en la edad (65 vs 68,9 años), ASA, ni en la transfusión intraoperatoria. La duración de la intervención fue significativamente menor en el grupo RV- (6,1 vs 6,7; p= 0,05). La morbilidad grado III-IV de Clavien fue del 14,2% en el grupo RV- y del 16,6% en el grupo RV+ (p=0,87). No hubo diferencias en la mortalidad hospitalaria (0% vs 5,5%), ni en la estancia hospitalaria (14,4 vs 15,2 días). La afectación del margen quirúrgico fue más frecuente en el grupo RV+ (18% vs 50%; p=0,003). La supervivencia al año, 3 y 5 años fue del 77, 34 y 11% en el grupo RV-,y del 92, 23 y 8% en el grupo con resección venosa. Conclusiones: La DPC con resección venosa puede realizarse con tasas de morbi-mortalidad similares a la DPC estándar. La supervivencia no muestra diferencias significativas entre los dos grupos. La resección venosa puede aumentar la resecabilidad en un grupo seleccionado de pacientes con adenocarcinoma de páncreas

Three‐dimensional modelling as a novel interactive tool for preoperative planning for complex perianal fistulas in Crohn's disease

AimThe aim of this study is to demonstrate the added value of three-dimensional (3D) reconstruction models and artificial intelligence for preoperative planning in complex perianal Crohn's disease. MRI is the gold standard for diagnosis of complex perianal fistulas and abscess due to its high sensitivity, but it lacks high specificity values. This creates the need for better diagnostic models such as 3D image processing and reconstruction (3D-IPR) with artificial intelligence (AI) algorithms. MethodThis is a prospective study evaluating the utility of 3D reconstruction models from MRI in four patients with perineal Crohn's disease (pCD). ResultsFour pCD patients had 3D reconstruction models made from pelvic MRI. This provided a more visual representation of perianal disease and made possible location of the internal fistula orifice, seton placement in fistula tracts and abscess drainage. ConclusionThree-dimensional reconstruction in CD-associated complex perianal fistulas can facilitate disease interpretation, anatomy and surgical strategy, potentially improving preoperative planning as well as intraoperative assistance. This could probably result in better surgical outcomes to control perianal sepsis and reduce the number of surgical procedures required in these patients

Three-dimensional modelling as a novel interactive tool for preoperative planning for complex perianal fistulas in Crohn's disease

Aim: The aim of this study is to demonstrate the added value of three-dimensional (3D) reconstruction models and artificial intelligence for preoperative planning in complex perianal Crohn's disease. MRI is the gold standard for diagnosis of complex perianal fistulas and abscess due to its high sensitivity, but it lacks high specificity values. This creates the need for better diagnostic models such as 3D image processing and reconstruction (3D-IPR) with artificial intelligence (AI) algorithms. Method: This is a prospective study evaluating the utility of 3D reconstruction models from MRI in four patients with perineal Crohn's disease (pCD). Results: Four pCD patients had 3D reconstruction models made from pelvic MRI. This provided a more visual representation of perianal disease and made possible location of the internal fistula orifice, seton placement in fistula tracts and abscess drainage. Conclusion: Three-dimensional reconstruction in CD-associated complex perianal fistulas can facilitate disease interpretation, anatomy and surgical strategy, potentially improving preoperative planning as well as intraoperative assistance. This could probably result in better surgical outcomes to control perianal sepsis and reduce the number of surgical procedures required in these patients

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease

BACKGROUND & AIMS: Therapies for perianal fistulas in patients with Crohn's disease are often ineffective in producing long-term healing. We performed a randomized placebo-controlled trial to determine the long-term efficacy and safety of a single local administration of allogeneic expanded adipose-derived stem cells (Cx601) in patients with Crohn's disease and perianal fistulas. METHODS: We performed a double-blind study at 49 hospitals in Europe and Israel, comprising 212 patients with Crohn's disease and treatment-refractory, draining, complex perianal fistulas. Patients were randomly assigned (1:1) to groups given a single local injection of 120 million Cx601 cells or placebo (control), in addition to the standard of care. Efficacy endpoints evaluated in the modified intention-to-treat population (randomly assigned, treated, and with 1 or more post-baseline efficacy assessment) at week 52 included combined remission (closure of all treated external openings draining at baseline with absence of collections >2 cm, confirmed by magnetic resonance imaging) and clinical remission (absence of draining fistulas). RESULTS: The study's primary endpoint, at week 24, was previously reported (combined remission in 51.5% of patients given Cx601 vs 35.6% of controls, for a difference of 15.8 percentage points; 97.5% confidence interval [CI] 0.5-31.2; P = .021). At week 52, a significantly greater proportion of patients given Cx601 achieved combined remission (56.3%) vs controls (38.6%) (a difference of 17.7 percentage points; 95% CI 4.2-31.2; P = .010), and clinical remission (59.2% vs 41.6% of controls, for a difference of 17.6 percentage points; 95% CI 4.1-31.1; P = .013). Safety was maintained throughout week 52; adverse events occurred in 76.7% of patients in the Cx601 group and 72.5% of patients in the control group. CONCLUSION: In a phase 3 trial of patients with Crohn's disease and treatment-refractory complex perianal fistulas, we found Cx601 to be safe and effective in closing external openings, compared with placebo, after 1 year. ClinicalTrials.gov no: NCT01541579